false
0001782107
0001782107
2026-10-22
2026-10-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 22, 2026
Onconetix,
Inc.
(Exact
Name of Registrant as Specified in its Charter)
| Delaware |
|
001-41294 |
|
83-2262816 |
(State or other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
| 201
E. Fifth Street, Suite 1900, Cincinnati, Ohio |
|
45202 |
| (Address of Principal Executive
Offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (513) 620-4101
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☒ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of Each Exchange on Which Registered |
| Common Stock, par value
$0.00001 per share |
|
ONCO |
|
The Nasdaq Stock Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01. Other Events.
On
October 22, 2026, Onconetix, Inc. (the “Company”) made an additional advance of $500,000 to Realbotix, LLC (“Realbotix”)
pursuant to that certain Grid Promissory Note, dated September 11, 2026 (the “Note”), previously disclosed in the Company’s
Current Report on Form 8-K filed with the Securities and Exchange Commission on September 14, 2026 (the “Prior Form 8-K”).
As
previously disclosed, pursuant to the Note, the Company agreed to make available to Realbotix loans in an aggregate principal amount
of up to $5.0 million, of which $2.5 million was advanced on September 11, 2026. Following the additional $500,000 advance, the aggregate
principal amount outstanding under the Note is $3.0 million.
The
terms of the Note remain unchanged. The description of the Note contained in the Prior Form 8-K is incorporated herein by reference.
Item
9.01. Exhibits.
| Exhibit
No. |
|
Description |
| 104 |
|
Cover Page Interactive
Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
| |
Onconetix, Inc. |
| |
|
| Dated: October 23, 2026 |
By: |
/s/
David A. White |
| |
|
David A. White |
| |
|
Chief Executive Officer |
